Repros At A Loss After FDA Abruptly Cancels Enclomiphene Panel Review
This article was originally published in The Pink Sheet Daily
Real reason behind cancelled Nov. 3 advisory committee meeting relates to secondary hypogonadism indication, company says, not concerns about analytical validation as FDA claimed.
You may also be interested in...
US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.
US FDA advisory committee's insistence on symptom benefit as an efficacy endpoint for obesity-related secondary hypogonadism highlights importance of Repros' current efforts to lay groundwork for a patient-reported outcomes instrument for further study of enclomiphene.
Clinical trials should go beyond merely demonstrating maintenance of spermatogenesis, US FDA says, but drug developers assert an increase in serum testosterone levels and/or improvement or maintenance of sperm concentration are appropriate clinical measures to support approval.